Nuvalent (NASDAQ:NUVL) Stock Rating Lowered by Barclays

Nuvalent (NASDAQ:NUVL) was downgraded by Barclays from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Several other analysts have also weighed in on NUVL. Stifel Nicolaus set a $124.00 price objective on shares of Nuvalent in a research note on Tuesday. TD Cowen lowered shares of Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 price target for the company. in a research note on Tuesday. Wedbush lowered shares of Nuvalent from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $125.00 to $124.00 in a research note on Tuesday. Robert W. Baird set a $122.85 price target on shares of Nuvalent in a research note on Tuesday. Finally, UBS Group lowered shares of Nuvalent from a “buy” rating to a “neutral” rating and decreased their price target for the company from $138.00 to $124.00 in a research note on Wednesday. Five analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $131.15.

Nuvalent Stock Performance

Shares of NASDAQ NUVL opened at $123.35 on Tuesday. The company has a market capitalization of $9.74 billion, a P/E ratio of -20.35 and a beta of 1.15. Nuvalent has a 52-week low of $71.13 and a 52-week high of $123.62. The company’s 50 day moving average price is $103.44 and its 200-day moving average price is $103.19.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the previous year, the business posted ($1.18) EPS. Analysts forecast that Nuvalent will post -5.74 earnings per share for the current year.

Insider Buying and Selling at Nuvalent

In other news, insider Deborah Ann Miller sold 5,500 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the sale, the insider owned 59,634 shares in the company, valued at $6,430,930.56. This represents a 8.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total transaction of $323,156.64. Following the completion of the sale, the insider owned 65,604 shares of the company’s stock, valued at approximately $6,854,305.92. The trade was a 4.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 126,953 shares of company stock worth $12,612,264. Company insiders own 5.02% of the company’s stock.

Institutional Trading of Nuvalent

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after acquiring an additional 108 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Nuvalent by 141.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after acquiring an additional 195 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Nuvalent in the 3rd quarter worth $38,000. NBC Securities Inc. bought a new stake in shares of Nuvalent in the 4th quarter worth $125,000. Finally, KBC Group NV grew its stake in shares of Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after acquiring an additional 297 shares in the last quarter. Institutional investors own 97.26% of the company’s stock.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.